Patient Registries and Natural History Studies in DMD

Patient registries and natural history studies in Duchenne muscular dystrophy are organised databases of clinical, functional, and demographic information about people living with the disease. They are how the field knows what an untreated trajectory looks like, how new therapies should be compared against expectation, and how regulators evaluate evidence in a condition too rare for very large traditional trials. They matter to families because enrollment is one of the most concrete ways a single patient can help the broader community.

This post is a practical overview. Registration decisions belong to the family in consultation with the care team.

Why registries matter in DMD

Three reasons sit at the centre:

• Natural-history baseline. Without standardised long-term data on untreated DMD, it is impossible to interpret whether a new therapy actually changes the disease. Registries provide that comparison group.
• Trial recruitment. When a new clinical trial opens, sponsors need to find eligible patients quickly. Registries with structured genetic and clinical data accelerate that match.
• Care quality and research questions. Registries surface patterns that individual clinics never see: rare complications, regional differences in care, the impact of specific medications across the population.

The CINRG Duchenne Natural History Study, one of the largest prospective DMD cohorts, has provided the comparator data used to evaluate multiple newer therapies. (CINRG Duchenne Natural History Study)

The major registries and natural history programs

A non-exhaustive list, grouped by scope.

Multi-site clinical research networks

• CINRG (Cooperative International Neuromuscular Research Group) — long-running multicentre natural history study with detailed annual assessments including timed function tests, NSAA, pulmonary and cardiac measures, and quality of life. Over 400 patients enrolled across more than a decade.
• MDA Care Center Network — connects more than 150 specialised neuromuscular clinics across the United States and contributes to research and care standardisation.

Patient-led international registries

• The Duchenne Registry (formerly DuchenneConnect), administered by Parent Project Muscular Dystrophy, is a patient and family self-report registry that has supported numerous research projects and trial recruitment efforts.
• TREAT-NMD is an international neuromuscular network connecting national patient registries across Europe, Asia, the Americas, and beyond. National branches collect locally and contribute to international research questions.

Population-level surveillance

• MD STARnet (Muscular Dystrophy Surveillance, Tracking, and Research Network) is a population-based surveillance system in the United States operated through the Centers for Disease Control and Prevention. It provides epidemiological data on disease prevalence, care delivery, and outcomes.

Country-specific examples

• Remudy (Japan), UK NorthStar Network, Italian DMD Registry, DMD Network Brazil, and many others.

What registries collect

Specifics vary, but common data elements include:

• Confirmed genetic mutation.
• Date of birth, age at diagnosis, age at key milestones.
• Functional assessments (NSAA, 6MWT, PUL, timed function tests).
• Pulmonary and cardiac measures over time.
• Medication history, including corticosteroids and disease-modifying therapies.
• Quality of life and patient-reported outcomes.
• Trial participation history.

For background on the measures, see functional assessments in DMD.

How registries support clinical decisions

Registry data has informed several practical questions in routine care:

• The expected timeline of loss of ambulation under different corticosteroid regimens.
• The cardiac and respiratory trajectory in steroid-treated versus steroid-untreated patients.
• The impact of scoliosis surgery on long-term outcomes.
• The benefit profile of newer therapies, including ataluren and others, compared against natural-history controls. (Ataluren effectiveness vs CINRG DNHS, PMC)

For background, see the DMD clinical trial reading guide.

How families join

Specifics depend on the registry, but the general pattern is:

• The Duchenne Registry uses an online enrollment with self-reported clinical information that can be updated over time. The care team can be authorised to contribute structured data.
• CINRG and similar prospective studies enrol through participating clinical sites. Eligibility is reviewed at the site, and participation involves periodic structured visits.
• TREAT-NMD national registries follow country-specific enrollment pathways usually coordinated through neuromuscular clinics.

A practical first step is to ask the neuromuscular care team which registries the site supports and which the family is already eligible to join.

What participation involves

Common elements families can expect:

• Initial enrollment form covering demographics, diagnosis, mutation, and medications.
• Periodic updates (annual or biannual) covering clinical changes and milestones.
• For some registries, in-clinic structured assessments and additional research visits.
• Optional consent to be contacted about specific clinical trials when eligibility matches.
• The ability to update or withdraw consent at any time.

Most registries do not provide care or compensation; their value is collective rather than individual.

Privacy and data use

Registries collect identifying information and detailed health data. Reputable registries publish their privacy policies, follow national data-protection regulations (HIPAA, GDPR, LGPD, and equivalents), and describe how data is shared with researchers and sponsors. Reading those policies before consent is reasonable.

For families uncertain about privacy implications, the DMD care team and patient organisations such as Parent Project Muscular Dystrophy can help interpret the documents.

Why broad enrollment matters

The clinical and regulatory power of registry data depends on representativeness. When registries underrepresent certain populations (geographic, ethnic, socioeconomic), the natural-history baseline they provide becomes biased and the conclusions drawn from comparisons can be wrong. Broad participation is part of how the field corrects for that.

This is why many patient organisations actively encourage enrollment as a community contribution, especially for patients in groups that have been historically underrepresented.

For background, see working with DMD patient organizations.

What is still uncertain

Optimal integration between different registries, the role of decentralised and patient-driven data collection, and the use of real-world data in regulatory decisions continue to evolve.

The reasonable framing is that registry participation is a low-cost, high-value contribution that any DMD family can make to the future of the disease. The decisions about which to join and at what level belong to the patient, family, and care team.

For related reading, see the DMD clinical trial reading guide, functional assessments in DMD, working with DMD patient organizations, and the DMD research pipeline.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.